Maxillary Sinus Augmentation

§4.3.1 — Overview

The atrophic posterior maxilla

The posterior maxilla is the most demanding site in routine implant dentistry, and it is demanding for a single anatomical reason: the maxillary sinus pneumatizes into the alveolus from above while crestal resorption advances from below, so the vertical bone available for an implant is squeezed from both directions. After a posterior tooth is lost, the floor of the sinus tends to drop further toward the crest, and within a few years the residual bone height (RBH) beneath the sinus floor may be only a few millimetres. Maxillary sinus floor augmentation — grafting beneath the elevated Schneiderian membrane to recreate a bony platform — is the procedure that makes implant placement possible in this setting, and it is one of the most thoroughly studied bone-augmentation techniques in the literature.¹

Two operations dominate practice, and choosing between them is the central decision of this chapter. The transcrestal (crestal, osteotome) approach reaches the sinus floor through the implant osteotomy itself, fracturing the floor upward and elevating the membrane blindly to gain a modest amount of height. The lateral window approach opens a bony window in the lateral antral wall, lifts the membrane under direct vision, and packs graft into the created space — more invasive, but capable of large and predictable vertical gains. A third axis cuts across both: whether the implant is placed at the same visit (simultaneous) or after the graft has matured (staged). That choice turns almost entirely on whether enough native bone remains to obtain primary stability at the moment of placement.²³

The organising variable that ties these decisions together is residual bone height, and the discipline of this chapter is to read RBH off the cone-beam CT (CBCT), translate it into an approach and a timing, and then check that translation against the membrane, the anatomy, and any sinus pathology — any one of which can override what the millimetres alone would suggest.¹

Residual bone height proposes the approach; the membrane, the anatomy, and primary stability dispose of it.

◆ Key concept · Two questions, in order

Question one — how much vertical bone do I need to add? This sets the approach: a modest lift (roughly 2–4 mm) is well served by the transcrestal route, whereas a large gain demands the lateral window with its direct membrane access and superior graft volume. Question two — can I obtain primary stability in the native bone today? This sets the timing: if a stable implant can be seated in the residual ridge, place it simultaneously; if not, graft first and stage the implant after maturation. RBH is the single number that most strongly predicts both answers, which is why it is read first and weighed against everything else.

§4.3.2 — Pre-surgical assessment

Assess before you choose

Residual bone height is the primary determinant, but it is not the only one, and the experienced operator reads the CBCT for a small set of findings that can change the plan before a flap is raised. The decision is never made on a panoramic radiograph: only cross-sectional imaging shows the true vertical bone, the membrane, the antral septa, and the course of the alveolar antral artery. The four domains below — measure, check, rule out, modify — structure that read.¹

First, measure the vertical bone below the sinus floor at every planned implant site, not merely at the most atrophic one; the floor is rarely flat, and septa or a recessus can give one site adequate height while its neighbour has almost none. Second, check the Schneiderian membrane and the local anatomy: membrane thickness (a healthy membrane is roughly 1 mm; marked thickening suggests inflammation or a retention cyst), the presence and height of bony septa that subdivide the sinus, the patency of the ostium that must drain the operated sinus, the thickness of the lateral wall the bur will cut, and the position of the alveolar antral artery within that wall. Third, rule out active sinus pathology — acute or chronic sinusitis, large mucoceles or odontogenic cysts, or an obstructed ostium — and refer to otolaryngology where indicated, optimising the sinus before any graft is placed. Fourth, modify the plan for patient-level risk: smoking impairs graft healing and raises membrane and infective complications, and allergic rhinitis or prior sinus surgery alters both consent and prognosis.¹³

Table 1 · Pre-surgical CBCT assessment for sinus augmentation
Domain	What to evaluate	Why it matters	Evidence
Measure	Residual bone height below the floor; bucco-palatal width; floor contour and septa	RBH governs approach and timing; width governs implant feasibility; septa fragment the lift	Consensus
Check	Schneiderian membrane thickness; ostium patency; lateral wall thickness; alveolar antral artery	Thick membrane, blocked ostium, intra-osseous artery and thick wall all raise perforation and complication risk	Syst. review
Rule out	Acute/chronic sinusitis; large cysts/mucoceles; opacification	Active pathology must be treated first; refer to ENT before grafting	Consensus
Modify	Smoking; allergic rhinitis; prior sinus surgery; uncontrolled comorbidity	Alters graft healing, complication rate, consent and prognosis	Syst. review

▲ Common pitfall · Planning off a panoramic

A panoramic radiograph systematically misrepresents the posterior maxilla — it cannot show membrane thickening, septa, ostial patency, or the alveolar antral artery, and it distorts vertical height. Selecting an approach without a CBCT is the most common avoidable error in sinus surgery and a recurrent cause of intra-operative surprise. CBCT is mandatory.¹

§4.3.3 — Approach selection

From residual bone height to a plan

The cleanest way to think about approach selection is as a set of RBH bands, each carrying a default approach and a default timing, with primary stability acting as the tie-breaker in the middle of the range. The figure below shows the two operations in cross-section; the table that follows resolves each band into a recommendation with its evidence grade. The thresholds are ranges, not rules: the literature places the principal cut-point around 4–5 mm, with simultaneous placement reliable when roughly 5–6 mm or more of native bone remains and staging favoured below that, but membrane anatomy, bone density, implant design, and operator experience all shift the boundaries.¹²³

Figure 1. The two sinus-augmentation approaches in cross-section. Left: the transcrestal route elevates the membrane a few millimetres through the implant osteotomy, with the implant placed simultaneously when residual bone height permits primary stability. Right: the lateral window opens the antral wall for direct membrane elevation and large graft volume, with implant placement staged when native bone is too thin to stabilise an implant. Adapted from contemporary sinus-augmentation consensus and systematic reviews.¹²³

The RBH bands

At ≥ 8–10 mm of residual bone, most posterior sites accept a standard-length implant with no sinus elevation at all; a minor crestal lift is reserved for the case that needs a few extra millimetres of engagement, and bucco-palatal width is confirmed separately. At 6–8 mm, a modest transcrestal lift of 2–4 mm with simultaneous placement is both predictable and minimally invasive — this is the heartland of the osteotome and crestal-drilling techniques. The 4–6 mm band is the genuinely borderline zone: either approach can succeed, and the decision is handed to whether primary stability can actually be obtained — if it can, place simultaneously by whichever route; if it cannot, default to a lateral window with staged placement. Below 4 mm, the vertical deficit is large and native bone too thin to stabilise an implant, so the lateral window with grafting and staged placement after maturation is the standard.¹²³

Table 2 · Residual bone height bands → approach & timing
RBH band	Default approach	Implant timing	Typical gain / notes	Evidence
≥ 8–10 mm	Often no lift; standard placement	Simultaneous	Minor crestal lift only if engaging floor for length; confirm width	Consensus
6–8 mm	Transcrestal (osteotome / crestal)	Simultaneous	~2–4 mm gain; stability reliably achievable	Syst. review
4–6 mm	Transcrestal or lateral — stability decides	Simultaneous if stable; else staged	Comparable 12-mo stability between approaches in this range	Syst. review
< 4 mm	Lateral window + graft	Staged (~6–9 mo)	Large vertical gain; re-image before placement	Consensus

Approach comparison

Holding the two operations side by side clarifies the trade-off. The transcrestal route is faster and far less morbid but elevates the membrane blindly, limiting both the achievable height and the operator's ability to detect and manage a perforation. The lateral window costs a flap, a bony window, and greater post-operative morbidity, but buys direct visualisation, larger and more predictable gains, and the ability to repair a torn membrane under vision. Neither is universally superior; each maps onto a region of the RBH axis.²³

Table 3 · Transcrestal vs lateral window — operative comparison
Feature	Transcrestal (osteotome / crestal)	Lateral window
Typical RBH	≥ 5–6 mm	< 4–5 mm
Vertical gain	~2–4 mm	Larger, more predictable gain
Implant timing	Usually simultaneous	Simultaneous if stability obtainable, else staged
Morbidity	Lower; less invasive, no lateral flap	Higher; flap + lateral wall window
Membrane access	Blind elevation through osteotomy	Direct visualisation & repair
Perforation handling	Hard to detect or repair	Visualised; repairable (collagen / suture)

Interactive approach selector

Select the residual bone height band measured on CBCT to review the recommended approach, timing, and operative steps. Thresholds are typical ranges; membrane anatomy and operator experience shift the boundaries.

Tap a residual bone height band.

✦ Clinical pearl · Let stability, not the calendar, decide timing

In the 4–6 mm band the literature shows comparable twelve-month stability whether the implant is placed simultaneously or staged, provided primary stability is genuinely achieved at placement. The decision is therefore made on the table, with the implant in hand: if it seats with good insertion torque and an acceptable stability reading, place it; if it spins or feels under-stabilised in the thin native bone, abandon simultaneous placement, complete the graft, and stage. Forcing a simultaneous implant into inadequate bone to save a visit trades a small convenience for a real risk of failure.²

▲ Common pitfalls

Reading RBH from a panoramic and choosing transcrestal for a site that, on CBCT, has a septum or < 4 mm of true vertical bone.
Attempting a large transcrestal lift (> 4 mm) blindly — perforation risk rises sharply and is hard to detect without direct vision.
Grafting into an obstructed or actively infected sinus; an unaddressed ostial block predisposes to graft infection and failure.
Placing a simultaneous implant in the < 4 mm band on the assumption that the graft will "hold" it — it will not provide primary stability.

§4.3.4 — Glossary

Key terms

Residual bone height (RBH): The vertical thickness of native bone between the alveolar crest and the floor of the maxillary sinus; the primary determinant of sinus-augmentation approach and implant timing.
Schneiderian membrane: The thin (≈1 mm) bilaminar mucoperiosteal lining of the maxillary sinus that is elevated, intact, to create the space grafted in sinus augmentation.
Transcrestal sinus floor elevation: Membrane elevation performed through the implant osteotomy (osteotome or crestal drilling), giving a modest, blind lift; usually with simultaneous implant placement.
Lateral window approach: Membrane elevation through a window cut in the lateral antral wall, allowing direct visualisation, large graft volumes, and membrane repair.
Simultaneous placement: Implant inserted at the same surgical visit as the graft, possible only when residual bone provides primary stability.
Staged placement: Implant inserted after the graft has matured (typically ~6–9 months), used when native bone cannot stabilise an implant at grafting.
Ostium: The drainage opening of the maxillary sinus into the middle meatus; its patency must be confirmed before grafting.
Alveolar antral artery: An anastomosing vessel that may run within the lateral antral wall; its position must be checked on CBCT to avoid haemorrhage during a lateral window.
Antral septum: A bony ridge (septum of Underwood) that subdivides the sinus floor, fragmenting the elevation space and raising perforation risk.

§4.3.S — Self-test

Self-Test

1. The single variable that most strongly determines both the sinus-augmentation approach and the implant timing is:

A is correct. Residual bone height (RBH) is the organising variable: it predicts how much vertical gain is needed (approach) and whether primary stability can be obtained today (timing). Other factors modify, but do not replace, RBH.

2. The mandatory imaging modality for planning a sinus augmentation is:

C is correct. Only cross-sectional CBCT reliably shows true vertical bone, membrane thickness, septa, ostial patency, and the alveolar antral artery. Panoramic imaging distorts height and hides these structures.

3. A site has 7 mm of residual bone below the sinus floor. The most appropriate plan is:

B is correct. In the 6–8 mm band, a modest transcrestal lift of ~2–4 mm with simultaneous placement is predictable and minimally invasive; primary stability is reliably achievable in this much native bone.

4. A site has 3 mm of residual bone below the floor. The standard plan is:

B is correct. Below ~4 mm the vertical deficit is large and native bone too thin for primary stability, so a lateral window with grafting and staged placement (after ~6–9 months of maturation) is standard.

5. In the 4–6 mm residual bone band, the factor that should decide between simultaneous and staged placement is:

B is correct. This is the borderline zone; outcomes are comparable when stability is achieved. If a stable implant can be seated, place simultaneously; if not, graft and stage.

6. The principal advantage of the lateral window over the transcrestal approach is:

B is correct. The lateral window allows the membrane to be elevated and, if torn, repaired under direct vision, and it accommodates large graft volumes — at the cost of greater morbidity than the transcrestal route.

7. The typical vertical gain expected from a transcrestal (osteotome/crestal) elevation is approximately:

B is correct. The transcrestal route reliably yields a modest gain of about 2–4 mm. Attempting much more blindly through the osteotomy sharply increases perforation risk.

8. The Schneiderian membrane is best described as:

B is correct. The Schneiderian membrane is the thin bilaminar lining of the sinus; it is elevated intact to create the space that is grafted. Marked thickening suggests inflammation or a retention cyst.

9. Before grafting, an obstructed sinus ostium should be addressed because:

B is correct. A patent ostium is needed for the operated sinus to drain. An unaddressed ostial block predisposes to post-operative sinusitis and graft infection; refer to ENT and optimise first.

10. The structure whose position within the lateral antral wall must be checked on CBCT to avoid haemorrhage during a lateral window is the:

B is correct. The alveolar antral artery (an anastomosis of the posterior superior alveolar and infraorbital arteries) may run within the lateral wall; cutting it during the window can cause troublesome bleeding.

11. An antral septum (septum of Underwood) is relevant to sinus elevation because it:

B is correct. Septa partition the sinus floor and complicate membrane elevation, increasing the chance of perforation; they must be identified on CBCT and the window/technique adapted.

12. With ≥ 8–10 mm of residual bone in the posterior maxilla, the usual plan is:

A is correct. With ≥ 8–10 mm there is usually enough vertical bone for conventional placement; a minor crestal lift is reserved for cases needing a little extra engagement for length.

13. Marked Schneiderian membrane thickening on CBCT should prompt the clinician to:

B is correct. A healthy membrane is ~1 mm; pronounced thickening suggests inflammation, a retention cyst, or sinusitis, which should be evaluated and managed (ENT referral where indicated) before grafting.

14. Compared with the lateral window, the transcrestal approach carries:

A is correct. The transcrestal route is less invasive but elevates the membrane blindly through the osteotomy, limiting both achievable height and the ability to detect and repair perforations.

15. Smoking is relevant to sinus augmentation planning chiefly because it:

B is correct. Smoking impairs graft incorporation and is associated with higher complication and failure rates; it should modify consent, prognosis, and ideally be reduced before surgery.

16. In a staged lateral window protocol, implant placement is typically deferred for approximately:

B is correct. Staged grafts are usually allowed ~6–9 months to consolidate before implant placement, and the site should be re-imaged to confirm graft maturation prior to surgery.

17. Active acute maxillary sinusitis discovered at planning should lead the clinician to:

B is correct. Active sinus pathology is a contraindication to grafting until resolved; it must be treated and the sinus optimised first to avoid graft infection and failure.

18. The thresholds quoted for RBH bands (e.g., ~4–5 mm cut-point) are best regarded as:

B is correct. The literature reports cut-points around 4–5 mm, but these are ranges, not fixed laws; membrane anatomy, bone quality, implant design, and experience legitimately move the boundaries.

19. Why should residual bone height be measured at every planned implant site rather than once?

B is correct. The sinus floor undulates and may carry septa or a recessus, so one site may have adequate bone while its neighbour has almost none — each planned site is measured separately.

20. Forcing a simultaneous implant into < 4 mm of native bone "because the graft will support it" is unsound because:

C is correct. Primary stability is mechanical and comes from native bone, not unconsolidated graft. With < 4 mm of native bone, the graft cannot stabilise an implant, so staged placement after maturation is required.

1. A patient presents for posterior maxillary implants. Walk me through how you assess the case before choosing a sinus approach.

Model answer. I start with a CBCT — never a panoramic alone — because only cross-sectional imaging shows the true vertical bone and the relevant anatomy. I work through four domains. I measure residual bone height below the sinus floor at every planned site, plus bucco-palatal width and the floor contour, because the floor is irregular and one site can differ markedly from its neighbour. I check the Schneiderian membrane thickness, the patency of the ostium, the thickness of the lateral wall, the presence of septa, and the course of the alveolar antral artery. I rule out active sinus pathology — sinusitis, large cysts, an obstructed ostium — and refer to ENT where needed, optimising the sinus before grafting. Finally I modify for patient risk such as smoking, allergic rhinitis, or prior sinus surgery, which change consent and prognosis. Only then do I let RBH propose an approach.

Examiner follow-ups:

Why is a panoramic inadequate here?
What membrane thickness would concern you, and why?

2. Explain how residual bone height maps onto your choice of approach and timing, band by band.

Model answer. I think in bands. At roughly 8–10 mm or more, most sites take a standard implant with no lift, or at most a minor crestal lift to gain a little engagement. At 6–8 mm, a transcrestal lift of about 2–4 mm with simultaneous placement is predictable and minimally invasive. The 4–6 mm band is the borderline zone where either approach can work and primary stability decides: if I can seat a stable implant I place simultaneously; if not, I graft by lateral window and stage. Below 4 mm, the deficit is large and the native bone too thin for stability, so I default to a lateral window with grafting and staged placement after roughly 6–9 months, re-imaging before I place. Throughout, I treat these numbers as ranges that anatomy, bone density, and my own experience can shift, not as fixed rules.

Examiner follow-ups:

What is the principal cut-point in the literature, and how firm is it?
How would dense versus soft bone move your boundary?

3. Compare the transcrestal and lateral window approaches and justify when you choose each.

Model answer. The transcrestal route reaches the sinus through the osteotomy, elevates the membrane blindly, and gains a modest 2–4 mm; it is fast and low-morbidity, with no lateral flap, but it limits achievable height and makes a perforation hard to detect or repair. The lateral window opens the antral wall, elevates the membrane under direct vision, and accommodates large, predictable graft volumes, and it lets me repair a torn membrane — at the cost of a flap, a window, and greater morbidity. So I choose transcrestal when RBH is adequate (roughly ≥ 5–6 mm) and I need only a small lift with simultaneous placement, and the lateral window when RBH is low (under about 4–5 mm), when I need a large gain, or when anatomy such as septa or a thick membrane makes a blind lift unsafe. In the borderline band, achievable primary stability is the tie-breaker.

Examiner follow-ups:

How does each approach handle a membrane perforation?
When would anatomy alone push you to a window despite adequate height?

4. Defend your decision to stage rather than place simultaneously in a patient with 3 mm of residual bone.

Model answer. Primary stability is a mechanical property that comes from the implant interlocking with native bone, and with only 3 mm of native bone beneath the floor there simply is not enough to stabilise an implant. Fresh, unconsolidated graft does not provide stability — it is a scaffold that must mature into bone over months. If I placed simultaneously I would be relying on a substrate that cannot resist micromotion, and I would expose the implant to a high risk of fibrous healing and failure. So I perform a lateral window with grafting, allow roughly 6–9 months for the graft to consolidate, re-image to confirm maturation, and then place the implant into a now-adequate bony platform with reliable primary stability. The slightly longer treatment is justified by the substantially better and more predictable outcome.

Examiner follow-ups:

Why can fresh graft not provide primary stability?
What would you check on the re-entry CBCT before placing?

5. A planning CBCT shows a thickened membrane, a low-lying alveolar antral artery, and an antral septum at the intended window. How does this change your plan, and what do you tell the patient?

Model answer. Each finding shifts my plan. The thickened membrane makes me suspect inflammation or a retention cyst, so I assess sinus health, treat or refer to ENT if there is active pathology, and confirm ostial patency before any graft — grafting into an inflamed or poorly draining sinus invites infection and failure. The low-lying alveolar antral artery within the lateral wall means I plan my window to avoid it, anticipate possible bleeding, and have haemostatic measures ready, since cutting it can produce troublesome haemorrhage. The septum subdivides the floor and fragments the elevation space, raising perforation risk, so I adapt the window design — sometimes a double window or a modified osteotomy around the septum — and elevate the membrane meticulously on both sides. Because all three raise the complication risk, I favour the lateral window for direct vision and repair capability, and I revise my consent: I tell the patient these anatomical factors increase the chance of membrane perforation, bleeding, and post-operative sinus problems, that I may need to stage or abort if the membrane cannot be safely elevated, and that we may involve an ENT colleague.

Examiner follow-ups:

How would you manage a perforation discovered during elevation?
Which of these three findings most changes your approach, and why?
What pre-operative steps reduce the bleeding risk from the artery?

§4.3 — References

References

Jensen OT, Shulman LB, Block MS, Iacono VJ. Report of the Sinus Consensus Conference of 1996. Int J Oral Maxillofac Implants. 1998;13(Suppl):11–45. PMID: 9715571
Pjetursson BE, Tan WC, Zwahlen M, Lang NP. A systematic review of the success of sinus floor elevation and survival of implants inserted in combination with sinus floor elevation. Part I: lateral approach. J Clin Periodontol. 2008;35(8 Suppl):216–240. doi:10.1111/j.1600-051X.2008.01272.x
Wallace SS, Tarnow DP, Froum SJ, Cho SC, Zadeh HH, Stoupel J, Del Fabbro M, Testori T. Maxillary sinus elevation by lateral window approach: evolution of technology and technique. J Evid Based Dent Pract. 2012;12(3 Suppl):161–171. doi:10.1016/S1532-3382(12)70030-1. PMID: 23040346
Stuhr SH, Saleh MHA, Testori T, Wang HL, Decker AM. Long-term stability of transcrestal sinus augmentation. Periodontol 2000. 2025. doi:10.1111/prd.70009
Lyu M, Xu D, Zhang X, Yuan Q. Maxillary sinus floor augmentation: a review of current evidence on anatomical factors and a decision tree. Int J Oral Sci. 2023;15(1):41. doi:10.1038/s41368-023-00248-x

Reference numbering follows the full reference set of the standard module; this prototype displays the subset cited in-text. Evidence grades: Systematic review Consensus Preclinical.

Maxillary Sinus Augmentation

The atrophic posterior maxilla

Assess before you choose

From residual bone height to a plan

The RBH bands

Approach comparison

Interactive approach selector

Key terms

Self-Test

Related modules

References

About this chapter